| [1] |
Khan SA, Emadossadaty S, Ladep NG,et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?[J]. J Hepatol, 2012, 56(4): 848-854.
|
| [2] |
Ramacciato G, Nigri G, Bellagamba R, et al. Univariate and multivariate analysis of prognostic factors in the surgical treatment of hilar cholangiocarcinoma[J]. Am Surg, 2010, 76(11): 1260-1268.
|
| [3] |
Nuzzo G, Giuliante F, Ardito F, et al. Intrahepatic cholangiocarcinoma: prognostic factors after liver resection[J]. Updates Surg, 2010, 62(1): 11-19.
|
| [4] |
Belmaker RH. Bipolar disorder[J]. N Engl J Med, 2004, 351(5): 476-486.
|
| [5] |
Shabbeer S, Kortenhorst MS, Kachhap S, et al. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo[J]. Prostate, 2007, 67(10): 1099-1110.
|
| [6] |
Kuendgen A, Gattermann N. Valproic acid for the treatment of myeloid malignancies[J]. Cancer, 2007, 110(5): 943-954.
|
| [7] |
Peñaranda Fajardo NM, Meijer C, Kruyt FA. The endoplasmic reticulum stress/ unfolded protein response in gliomagenesis, tumor progression and as a therapeutic target in Glioblastoma[J]. Biochem Pharmacol, 2016, DOI: 10.1016/j.bcp.2016.04.008[Epub ahead of print]. |
| [8] |
Liu N, Wang C, Wang L, et al. Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis[J]. Int J Mol Med, 2016, DOI: 10.3892/ijmm.2016.2552[Epub ahead of print]. |
| [9] |
Xie C, Edwards H, Lograsso SB, et al. Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells[J]. Pediatr Blood Cancer, 2012, 59(7): 1245-1251.
|
| [10] |
纪巧丽，林蓉，史晓莲，等．双丙戊酸钠和丙戊酸钠对HepG2细胞的毒性作用及机制[J]．中国药理学与毒理学杂志，2010, 24(3): 214-218.
|
| [11] |
Iwahashi S, Utsunomiya T, Imura S, et al. Effects of valproic acid in combination with S-1 on advanced pancreatobiliary tract cancers: clinical study phases I/II[J]. Anticancer Res, 2014, 34(9): 5187-5191.
|
| [12] |
Jenuwein T, Allis CD. Translating the histone code[J]. Science, 2001, 293(5532): 1074-1080.
|
| [13] |
Kuendgen A, Schmid M, Schlenk R, et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia[J]. Cancer, 2006, 106(1):112-119.
|
| [14] |
Iwahashi S, Ishibashi H, Utsunomiya T, et al. Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines[J]. J Med Invest, 2011, 58(1/2): 106-109.
|
| [15] |
Sriraksa R1, Limpaiboon T. Histone deacetylases and their inhibitors as potential therapeutic drugs for cholangiocarcinoma-cell line findings[J]. Asian Pac J Cancer Prev, 2013, 14(4):2503-2508.
|
| [16] |
Koyama M, Izutani Y, Goda AE, et al. Histone deacetylase inhibitors and 15-deoxy-Delta12,14-prostaglandin J2 synergistically induce apoptosis[J]. Clin Cancer Res, 2010, 16(8): 2320-2332.
|
| [17] |
Blaheta RA, Michaelis M, Natsheh I, et al. Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium[J]. Br J Cancer, 2007, 96(11): 1699-1706.
|
| [18] |
Hodges-Gallagher L, Valentine CD, Bader SE, et al. Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells[J]. Breast Cancer Res Treat, 2007, 105(3): 297-309.
|
| [19] |
Landreville S, Agapova OA, Matatall KA, et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma[J]. Clin Cancer Res, 2012, 18(2): 408-416.
|
| [20] |
Neri P, Tagliaferri P, Di Martino MT, et al. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor[J]. Br J Haematol, 2008, 143(4): 520-531.
|